Skip to content

Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Medication Adherence

Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Medication Adherence

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02432469
Acronym
MISSION-2
Enrollment
1000
Registered
2015-05-04
Start date
2015-06-30
Completion date
2016-12-31
Last updated
2015-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Bypass Grafting, Medication Adherence, Mobile Applications

Keywords

coronary artery bypass, medication adherence, secondary prevention, mobile applications

Brief summary

The study is a randomized controlled trial, having a plan to recruit 1000 patients underwent coronary artery bypass grafting in 1 of 5 participating sites in 2015, and randomized to either the intervention group or control group, to test the effectiveness of a smartphone based application (APP) focusing on improving patients medication adherence. Patients randomized to the intervention group install the APP in their smartphones with personnel information and physicians' medication descriptions. The APP reminds at the time of taking medications, educates them on secondary prevention for coronary artery disease, and collects their weekly situations by questionaires. Investigators will follow-up patients by face to face or telephone interview. The 6-month effects of the intervention are evaluated.

Detailed description

The aim of this study is to test the effectiveness of a smartphone based application (APP) on improvement of patients' adherence to medications after coronary artery bypass grafting. DESIGN AND PROCEDURES The study is a randomized controlled trial, having a plan to recruit 1000 patients underwent coronary artery bypass grafting in 2015, and randomized to either the intervention group or the control group, to test the effectiveness of a smartphone based APP focusing on improving patients medication adherence. Patients randomized to the intervention group install the APP and are intervened by it. The patients randomized to control group receive usual care. The investigators follow up patients in both groups by face to face or telephone interview at 3-month and 6-month after randomization. The 6-month effects of the intervention are evaluated. The APP contains education materials about secondary prevention of coronary artery disease, patients can surf and read easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback at 8 pm everyday. The APP also pushes one patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-administration on blood pressure, blood lipid, glucose, physical activity, diet and body weight. APP will push series of recommendations right after patients' finishing the questionnaire to help them improve secondary prevention. The coordinators from participating sites interview patients at the baseline, 3-month and 6-month after the randomization, for information of medication adherence, major events and outcomes after coronary artery bypass grafting and quality of life. The primary outcome measure is the Chinese version of the 8-item Morisky medication adherence scale which has already been validated in Chinese population.

Interventions

The APP contains education materials about secondary intervention of coronary artery disease, patients can surf and read them very easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback from patients at 8 pm every day. The APP also pushes a patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-management on blood pressure, blood lipid, blood glucose, physical activity, diet and body weight. APP pushes series of recommendations right after patients' finishing the questionnaire to help them improve their secondary prevention.

Sponsors

China National Center for Cardiovascular Diseases
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Underwent coronary artery bypass grafting in 2015

Exclusion criteria

* Does not use a smartphone * Can not install the study specific APP into his/her smartphone * Does not use 3 or more applications installed in his/her smartphone * Is incapable to understand texts in Chinese * Can not type numbers in his/her smartphone

Design outcomes

Primary

MeasureTime frameDescription
Medication adherence measured by Chinese version of the 8-item Morisky medication adherence scale (C-MMAC-8)6 monthspatients' medication adherence measured by C-MMAC-8 at 6-month after randomization, the scale of more than 7 is defined as adherence to medications

Secondary

MeasureTime frameDescription
Medication adherence measured by C-MMAC-83 monthpatients' medication adherence measured by C-MMAC-8 at 3-month after randomization, the scale of more than 7 is defined as adherence to medications
mortality at 6-month6 months
rate of major adverse cardiovascular or cerebral events at 6-month6 monthscomposite endpoint of all-cause death, myocardial infraction, stroke and repeat revascularization
rate of major adverse cardiovascular or cerebral events at 3-month3 monthscomposite endpoint of all-cause death, myocardial infraction, stroke and repeat revascularization
mortality at 3-month3 months

Other

MeasureTime frameDescription
pill count6 monthsthe number of tablets remaining divided by the number of tablets prescribed

Countries

China

Contacts

Primary ContactChenfei Rao, MD
raochenfeifuwai@126.com+861088396356
Backup ContactJunzhe Du, MD
djzlfia@163.com+8617801013899

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026